Recap: AdvanSix Q2 Earnings

  AdvanSix (NYSE:ASIX) reported its Q2 earnings results on Friday, August 5, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

 

AdvanSix (NYSE:ASIX) reported its Q2 earnings results on Friday, August 5, 2022 at 06:30 AM.

Here’s what investors need to know about the announcement.

Earnings

AdvanSix missed estimated earnings by 2.95%, reporting an EPS of $2.3 versus an estimate of $2.37.

Revenue was up $146.05 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.55 which was followed by a 1.34% drop in the share price the next day.

Here’s a look at AdvanSix’s past performance:

 

Quarter Q1 2022 Q4 2021 Q3 2021 Q2 2021
EPS Estimate 1.71 0.81 1.27 0.89
EPS Actual 2.26 0.80 1.51 1.53
Revenue Estimate 481.77M 408.30M 408.15M 408.55M
Revenue Actual 479.07M 424.06M 446.50M 437.68M

To track all earnings releases for AdvanSix visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

What’s Going On With Tesla Stock?

Tesla said it produced 433,371 vehicles in the first quarter, down from 440,808 year-over-year. The EV maker delivered 386,810 vehicles last quarter, down from 422,875 year-over-year. This was Tesla's first year-over-year decline in deliveries since 2020.

TSLA

Read More

‘Change To Classification Of Psilocybin And MDMA To Enable Prescribing By Authorized Psychiatrists’; Australia Allows Prescription of MDMA and Psilocybin in Groundbreaking Regulatory Change – Australian Government Department Of Health And Aged Care

https://www.tga.gov.au/news/media-releases/change-classification-psilocybin-and-mdma-enable-prescribing-authorised-psychiatrists From 1 July this year, medicines containing the psychedelic substances psilocybin and MDMA

CMPS